Biodefense Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.00 % |
| Fastest Growing Market | Europe |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Biodefense Market Analysis
The biodefense market is expected to record a CAGR of 4% over the forecast period.
COVID-19 had a significant impact on the overall healthcare industry. As per the article published in May 2022 by Disaster Medicine Public Health emergency, the COVID-19 pandemic's emergence has had a big impact on people's lives and the stability of the economy and society. The study depicted that during the pandemic outbreak, there was a shortage of testing and surveillance, leading to a common issue in the whole healthcare system. For the United States and its foreign interests, biothreats are anticipated to continue to be complicated and serious threats. Hence, COVID-19 had a significant impact on the biodefense market. Currently, since the lockdown restrictions were lifted, the industry has been recovering well. To combat rising biothreats, many countries have invested in modernizing biodefense infrastructure to replicate and support public health emergency preparation activities and, thus, are expected to boost the market in the coming years. For instance, in January 2022, integrated Viral Protection (IVP), a Texas-based technology business, released a new portable air filtration equipment that can eliminate airborne viruses in a single pass, including sub-micron versions producing COVID-19, anthrax spores, allergens, and other dangerous respiratory triggers. The patented biodefense indoor air protection system apparently eradicates SARS-CoV-2 (99.999%), anthrax spores (99.98%), and other airborne infections in a single pass.
The biodefense market is driven by factors such as the presence of favorable government initiatives, increasing investment by governments in developed countries, and rapid technological advancements. For instance, Emergent Bioscience announced that, for Q1 2022, revenues from Anthrax vaccines increased by USD 48.6 million as compared to Q1 2021. The increase is largely driven by the timing of deliveries to the United States government (USG), specifically the Strategic National Stockpile (SNS). Moreover, the company received an AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) contract modification in September 2021 valued at approximately USD 399 million to deliver additional AV7909 doses through March 2023.
Every year, governments are spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense market have huge opportunities to expand due to governments' drive to be prepared for any kind of bioterrorism. As per the 2022 news report, the Biden administration has prepared a new defense strategy against pandemics and other biological threats that applies lessons from COVID-19 and puts the white house at the center of any future United States. In June 2022, a revised National Biodefense Strategy was expected to provide clearer guidance on how the US government should respond to future health threats.
As per the factors mentioned above, the biodefense market is anticipated to witness growth over the forecast period. However, low penetration in developing and underdeveloped countries restrains the market growth.
Biodefense Market Trends
This section covers the major market trends shaping the Biodefense Market according to our research experts:
Anthrax Product Segment Expected to Witness Healthy Growth Over the Forecast Period
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. It occurs naturally in soil and commonly affects domestic and wild animals around the world. People can get sick with anthrax if they encounter infected animals or contaminated animal products.
The anthrax product segment is fueled by factors such as the increased outbreak of anthrax in the human population, favorable government initiatives, and research and development collaboration in the studied fields. For instance, as per the European Centre for Disease Prevention and Control (ECDC) Communicable Disease Threat Report, in July 2022, as per the media reported 15 human cases of cutaneous anthrax were linked to an anthrax outbreak in cattle in Sisak-Moslavina County following heavy rain in the area. Furthermore, in July 2022, the Croatian Ministry of Agriculture issued an order containing measures to prevent the emergence and spread of anthrax in the affected area, for instance, closure of affected areas, vaccination of animals, and additional prevention measures relating to humans.
The presence of competitors, mergers, acquisitions, product launches, and R&D initiatives boost the market growth. For instance, InBios International, Inc. conducted a clinical trial in 2020 under the title 'Evaluation of the Clinical Specificity of the Active Anthrax Detect Plus (AAD Plus) Lateral Flow Immunoassay (LFI),' with the objective of the study is to determine the estimated clinical specificity of the AAD Plus. Moreover, strategic activities by market players, such as mergers and acquisitions, are expected to propel the growth of the market. For instance, in April 2022, Heat Biologics, Inc. announced the completion of its acquisition of Elusys Therapeutics, Inc., a commercial-stage biodefense firm and developer of the anthrax therapy ANTHIM (obiltoxaximab). ANTHIM is approved for use in the United States and Canada, as well as in Europe and the United Kingdom, under the brand name Obiltoxaximab SFL.
Hence, as per the facts mentioned above, the anthrax products segment is likely to boost market growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
The primary growth driver of the biodefence market in North America is increased research and development in field studies and increasing government initiatives. For instance, as per the 2021 report from the National Association of County and City Health Officials, to address biological threats, the National Health Security Strategy (NHSS) and National Biodefense Strategy (NBS) focused on advancing the United States health security enterprise through prevention, preparedness, response, recovery, and mitigation efforts to combat infectious disease and biological threats. Furthermore, to safeguard the American people from biological threats, the NBS and National Security Presidential Memorandum 14 (NSPM-14) established a leadership structure and strategy to coordinate the complete range of biodefense efforts carried out across the U.S. Government. Together, the strategy and the memoranda produced a method for the first time of identifying and connecting gaps in the annual budget process.
Additionally, as per the immediate release in August 2022 from the U.S. Department of Health & Human Services, The U.S. Department of Health and Human Services (HHS) has facilitated an agreement between Bavarian Nordic and Grand River Aseptic Manufacturing (GRAM), a Michigan-based pharmaceutical contract manufacturer, to establish the first fill and finish line for the JYNNEOS vaccine in the U.S, a vaccine indicated for the prevention of smallpox and monkeypox disease. Furthermore, as per the news published in May 2022, Public Services and Procurement Canada issued a tender to purchase 500,000 doses of the Imvamune smallpox vaccine on behalf of the Public Health Agency of Canada from 2023 to 2028.
As per the factors mentioned above, North America is expected to register a high growth rate for the studied market over the forecast period.
Biodefense Industry Overview
The biodefence market is moderately fragmented and competitive. The biodefense market consists of players such as Emergent BioSolutions Inc., Siga Technologies Inc., Ology Bioservices, and Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.). Many companies are getting funds from the governments and are developing certain vaccines or products that are beneficial in terms of national biosecurity. As the government of the United States has planned to increase the funding for biodefense, these companies are expected to benefit from the same in the coming future.
Biodefense Market Leaders
-
Siga Technologies Inc.
-
Emergent BioSolutions Inc.
-
Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
-
XOMA Corporation
-
Dynavax Technologies
*Disclaimer: Major Players sorted in no particular order
Biodefense Market News
- June 2022: Emergent BioSolutions Inc. (NYSE:EBS) announced that the United States Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).
- May 2022: Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc. to acquire Chimerix's exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the United States Food and Drug Administration (FDA) for all age groups for the treatment of smallpox.
Biodefense Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Investment and Initiatives by the Governments in Developed Countries
- 4.2.2 Rapid Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Low Penetration in Developing and Underdeveloped Countries
-
4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Product
- 5.1.1 Anthrax
- 5.1.2 Botulism
- 5.1.3 Smallpox
- 5.1.4 Nuclear
- 5.1.5 Other Products
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle East and Africa
- 5.2.4.1 GCC
- 5.2.4.2 South Africa
- 5.2.4.3 Rest of Middle East and Africa
- 5.2.5 South America
- 5.2.5.1 Brazil
- 5.2.5.2 Argentina
- 5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Emergent BioSolutions Inc.
- 6.1.2 Siga Technologies Inc.
- 6.1.3 Bavarian Nordic
- 6.1.4 National Resilience, Inc.
- 6.1.5 Ichor Medical Systems
- 6.1.6 Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
- 6.1.7 Dynavax Technologies
- 6.1.8 XOMA Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityBiodefense Industry Segmentation
As per the scope of the report, biodefense constitutes the use of medical measures to protect individuals against bioterrorism, including interventions such as drugs and vaccinations. Furthermore, there is an improvement in terms of research and public health preparations to defend against biological attacks. There is an increasing awareness regarding synthetic biology, mainly for using biological organisms to reduce the burden of diseases, especially for improving agricultural yields. The Biodefense Market is segmented by Product (Anthrax, Botulism, Smallpox, Nuclear, and Other Products) and Geography (North America, Europe, Asia-Pacific, Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | Anthrax | |
| Botulism | ||
| Smallpox | ||
| Nuclear | ||
| Other Products | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Biodefense Market Research FAQs
What is the current Global Biodefense Market size?
The Global Biodefense Market is projected to register a CAGR of 4% during the forecast period (2024-2029)
Who are the key players in Global Biodefense Market?
Siga Technologies Inc., Emergent BioSolutions Inc., Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.), XOMA Corporation and Dynavax Technologies are the major companies operating in the Global Biodefense Market.
Which is the fastest growing region in Global Biodefense Market?
Europe is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Biodefense Market?
In 2024, the North America accounts for the largest market share in Global Biodefense Market.
What years does this Global Biodefense Market cover?
The report covers the Global Biodefense Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Biodefense Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Biodefense Industry Report
The global market for Biodefense is comprehensively analyzed in this industry report, which covers various segments such as Anthrax, Botulism, Smallpox, Nuclear, and other products. The market size and market share are detailed across different geographies, including North America, Europe, Asia-Pacific, Middle East, Africa, and South America. This market analysis provides valuable insights into the market trends and market growth, offering an extensive market forecast outlook.
Industry reports indicate that the biodefense market is poised for significant growth, driven by increasing investments and advancements in technology. The industry analysis highlights the critical role of market leaders in shaping the market dynamics. Market research and market data are crucial for understanding the current market value and predicting future market segmentation.
The report example includes detailed industry information and industry statistics, which are essential for stakeholders to make informed decisions. The industry outlook and market overview sections provide a comprehensive review of the market predictions and market trends. The report pdf, available for download, offers an in-depth market review and market forecast, supported by extensive industry research and market data.
Research companies play a pivotal role in providing accurate industry sales and industry size information, which is crucial for understanding the market growth rate. The industry trends and market outlook sections of the report highlight the key factors driving the market growth and the potential challenges that may arise.
In conclusion, this industry report on the biodefense market offers a thorough analysis of the market value, market segmentation, and market predictions. The report is an invaluable resource for stakeholders seeking to understand the market dynamics and make strategic decisions based on comprehensive industry research and market data.
